Q3 FY2026 · ended Sep 30, 2026 · Revenue $27.19M, -20.0% YoY · Filed Nov 4, 2026
Niagen Bioscience, Inc. (NAGE) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $27.2 million and a net loss of $1.2 million. As of Sep 30, 2026 it held $69.5 million in cash and investments and $2.1 million in total debt.
Revenue
$27.19M
-20.0% vs year-ago quarter
Net income
$-1.17M
-125.6% vs year-ago quarter
Operating cash flow
$2.62M
-28.9% vs year-ago quarter
Free cash flow
—
EPS
$-0.01
-120.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
79.20M
-0.8% vs year-ago quarter
Net cash
$67.43M
Q3 FY2026
Operating margin
3.9%
TTM
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- NAGE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Los Angeles, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1386570
- Former names
- ChromaDex Corp. (until Mar 10, 2025); CODY RESOURCES, INC. (until Jun 24, 2008)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $27.2M | $29.8M | $31.5M | $33.8M | $34.0M |
| Operating income | -$1.6M | $700,000 | $1.6M | $4.1M | $4.2M |
| Net income | -$1.2M | $963,000 | $6.3M | $4.1M | $4.6M |
| Diluted EPS | -$0.01 | $0.01 | $0.07 | $0.05 | $0.05 |
| Operating cash flow | $2.6M | $2.8M | -$1.2M | $679,000 | $3.7M |
| Total assets | $108.7M | $106.6M | $114.3M | $106.4M | $98.1M |
| Total liabilities | $25.6M | $24.1M | $32.0M | $29.9M | $27.5M |
| Stockholders' equity | $83.1M | $82.5M | $82.3M | $76.5M | $70.7M |
| Cash and investments | $69.5M | $66.7M | $66.5M | $64.8M | $64.3M |
| Total debt | $2.1M | $2.3M | $2.6M | $2.8M | $3.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 29, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 6, 2026 | May 6, 2026 |
All 981 Niagen Bioscience, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.